These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 30509294)

  • 21. Food Effect Study Design With Oral Drugs: Lessons Learned From Recently Approved Drugs in Oncology.
    Farha M; Masson E; Tomkinson H; Mugundu G
    J Clin Pharmacol; 2019 Apr; 59(4):463-471. PubMed ID: 30536979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
    Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
    Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Phase 0 exploratory clinical trials: literature review 2006-2009].
    Picat MQ; Houédé N; Chamorey E; Mathoulin-Pélissier S
    Bull Cancer; 2011 Jul; 98(7):753-9. PubMed ID: 21690036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical pharmacodynamics of anticancer drugs: a basis for extending the concept of dose-intensity.
    Evans WE
    Blut; 1988 Jun; 56(6):241-8. PubMed ID: 3289632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose escalation randomised study of efmarodocokin alfa in healthy volunteers and patients with ulcerative colitis.
    Wagner F; Mansfield JC; Lekkerkerker AN; Wang Y; Keir M; Dash A; Butcher B; Harder B; Orozco LD; Mar JS; Chen H; Rothenberg ME
    Gut; 2023 Aug; 72(8):1451-1461. PubMed ID: 36732049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
    Takimoto CH
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose escalation methods in phase I cancer clinical trials.
    Le Tourneau C; Lee JJ; Siu LL
    J Natl Cancer Inst; 2009 May; 101(10):708-20. PubMed ID: 19436029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial.
    Tiessen RG; Kennedy CA; Keller BT; Levin N; Acevedo L; Gedulin B; van Vliet AA; Dorenbaum A; Palmer M
    BMC Gastroenterol; 2018 Jan; 18(1):3. PubMed ID: 29304731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The ethics of phase 0 oncology trials.
    Abdoler E; Taylor H; Wendler D
    Clin Cancer Res; 2008 Jun; 14(12):3692-7. PubMed ID: 18559585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reviewing concomitant medications for participants in oncology clinical trials.
    McGahey KE; Weiss GJ
    Am J Health Syst Pharm; 2017 Apr; 74(8):580-586. PubMed ID: 28389457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug Exposure to Establish Pharmacokinetic-Response Relationships in Oncology.
    Solans BP; Garrido MJ; Trocóniz IF
    Clin Pharmacokinet; 2020 Feb; 59(2):123-135. PubMed ID: 31654368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics, safety and tolerability of Bencycloquidium bromide, a novel selective muscarinic M1/M3 receptor antagonist, after single and multiple intranasal doses in healthy chinese subjects: an open-label, single-center, first-in-human study.
    Sun L; Ding L; Wang Y; Zhou W; Yan Z; Sun W; Zhang H; Ou N; Chen X
    Drugs R D; 2012 Mar; 12(1):17-28. PubMed ID: 22339483
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Minimum Age Working Group.
    Gore L; Ivy SP; Balis FM; Rubin E; Thornton K; Donoghue M; Roberts S; Bruinooge S; Ersek J; Goodman N; Schenkel C; Reaman G
    J Clin Oncol; 2017 Nov; 35(33):3781-3787. PubMed ID: 28968169
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A survey of the way pharmacokinetics are reported in published phase I clinical trials, with an emphasis on oncology.
    Comets E; Zohar S
    Clin Pharmacokinet; 2009; 48(6):387-95. PubMed ID: 19650677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.
    Zandvliet AS; Schellens JH; Beijnen JH; Huitema AD
    Clin Pharmacokinet; 2008; 47(8):487-513. PubMed ID: 18611060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatic-targeted RNA interference provides robust and persistent knockdown of alpha-1 antitrypsin levels in ZZ patients.
    Turner AM; Stolk J; Bals R; Lickliter JD; Hamilton J; Christianson DR; Given BD; Burdon JG; Loomba R; Stoller JK; Teckman JH
    J Hepatol; 2018 Aug; 69(2):378-384. PubMed ID: 29572094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.